The Michael J Fox Foundation For Parkinsons Research
The Michael J Fox Foundation For Parkinsons Research
News Article | June 12, 2017
"Mobile technology has the potential to provide unprecedented insights into the lived experience of Parkinson's disease," says Sohini Chowdhury, deputy CEO at MJFF. "CIS-PD aims to speed development of tools to easily and objectively track Parkinson's, and mobile data can give a deeper understanding of therapeutic impact in both clinical and research settings." Advancing the Use of Technology in Patient Care CIS-PD is led by clinicians from four clinical trial centers: Northwestern University, IL; The University of Rochester, NY; The University of Alabama at Birmingham; and The University of Cincinnati, OH. Participating clinicians will enroll a total of 50 people with Parkinson's who have iPhones, and pair an Apple watch to their devices. For six months, the Fox Wearable Companion application will collect movement data from the watch and direct patients to manually enter information on their symptoms and experience with the disease outside of the clinic. A dashboard tool will chart each individual's medication adherence, symptom severity, daily activity level and nighttime movement. During study visits, clinicians will compare their observations to the data collected in the application and patients' reported experiences. In doing so, clinicians can assess the accuracy and utility of mobile data in clinical practice. "People with Parkinson's see their clinicians for a snapshot of time, on a few occasions each year," says Tanya Simuni, MD, director of the Parkinson's Disease and Movement Disorders Program at Northwestern University and CIS-PD lead investigator. "The Clinician Input Study can help substantiate the supplemental use of digital platforms to provide critical disease insights, individualize care and improve treatment plans." Technology Empowers Patients and Drives Research Over the course of the study, the Intel team will work with participating clinicians to make iterative improvements to the dashboard tool, ensuring the most useful information is captured. "Technology makes it easier to collect valuable information from people as they live their daily lives," says Chen Admati, advanced analytics manager at Intel. "Data collected through the Fox Wearable Companion application holds the power to improve patient care, and help create and refine analytical tools to speed scientific discovery." As part of MJFF's commitment to advancing field-wide developments, all CIS-PD data will be de-identified and made available to qualified Parkinson's researchers at the conclusion of the study. About The Michael J. Fox Foundation for Parkinson's Research As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $700 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us on the Web Facebook, Twitter, LinkedIn and Pinterest. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-michael-j-fox-foundation-launches-clinician-input-study-in-parkinsons-disease-to-evaluate-mobile-technology-in-clinical-care-300472287.html
News Article | July 20, 2017
"We're thrilled that PD research has been selected to travel to the International Space Station and honored to partner with CASIS on behalf of the PD community here on Earth," said Michael J. Fox in a video message played today at the International Space Station Research and Development Conference in Washington, DC. LRRK2 protein will be sent to the International Space Station (ISS) as part of the SpaceX CRS-12 cargo resupply mission scheduled for no earlier than August 10, 2017. As manager of the ISS U.S. National Laboratory, CASIS coordinates transfer of scientific materials to and from the ISS and work done in the laboratory. MJFF initiated this project and has supported work to ready the protein for growth in space. LRRK2 is a priority target of Parkinson's research and drug development. Mutations in the LRRK2 gene can cause Parkinson's disease and are linked to heightened levels of LRRK2 protein kinase (a type of protein that modifies other proteins). Therefore, researchers believe inhibiting LRRK2 may prevent or slow Parkinson's progression. Drug developers have experience and success with other kinase inhibitors, so LRRK2 protein is considered a highly "druggable" target. Also raising interest in this area are findings of shared pathology between LRRK2 mutation carriers and idiopathic Parkinson's patients — suggesting that LRRK2 inhibitors may treat a broader Parkinson's population. Hindering this line of drug development, though, is limited understanding of LRRK2's exact structure. Greater understanding of a protein's shape and structure helps scientists design therapies more likely to engage that protein and treat disease. The more you know about the cuts inside a lock, the easier it is to design a key that fits. Earth's strong gravitational field produces ground-grown versions of LRRK2 protein with low resolution. The microgravity conditions of the ISS laboratory allow proteins to collect into bigger crystal structures with fewer defects that may allow for higher resolution. "The unique environment of the International Space Station untethers research from restrictions imposed by gravity," said CASIS President and Executive Director Gregory H. Johnson. "CASIS is glad to partner with The Michael J. Fox Foundation to explore the structure of this important piece of the Parkinson's puzzle." MJFF funded Stefan Knapp, PhD, at the University of Frankfurt in Germany and Sebastian Mathea, PhD, at the University of Oxford in the United Kingdom to prepare the LRRK2 protein for transfer and crystallization on the ISS. These investigators — with Susan Taylor, PhD, of University of California, San Diego — will analyze the samples when returned from the ISS laboratory. After about a month of growth, the LRRK2 protein crystals will be packaged in the returning SpaceX Dragon spacecraft. This project is a piece of the MJFF roadmap around LRRK2. The Foundation drives research into the biology of this protein and provides research tools available easily at low cost. The MJFF-led landmark Parkinson's Progression Markers Initiative has built a cohort of LRRK2 mutation carriers contributing data and samples to identify biological markers of Parkinson's for diagnosis and tracking. And the Foundation's LRRK2 Safety Initiative answered fundamental questions about the safety of LRRK2 inhibitors that kept major pharmaceutical companies interested in this area of drug development. Today MJFF is working with regulators and drug developers to plot a clinical testing path for the field. About The Michael J. Fox Foundation for Parkinson's Research As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $700 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit www.michaeljfox.org.
Choi D.W.,Korea Institute of Science and Technology |
Armitage R.,Eli Lilly and Company |
Brady L.S.,U.S. National Institutes of Health |
Coetzee T.,National Multiple Sclerosis Society |
And 7 more authors.
Neuron | Year: 2014
Several large pharmaceutical companies have selectively downsized their neuroscience research divisions, reflecting a growing view that developing drugs to treat brain diseases is more difficult and often more time-consuming and expensive than developing drugs for other therapeutic areas, and thus represents a weak area for investment. These withdrawals reduce global neuroscience translational capabilities and pose a serious challenge to society's interests in ameliorating the impact of nervous system diseases. While the path forward ultimately lies in improving understandings of disease mechanisms, many promising therapeutic approaches have already been identified, and rebalancing the underlying risk/reward calculus could help keep companies engaged in making CNS drugs. One way to do this that would not require upfront funding is to change the policies that regulate market returns for the most-needed breakthrough drugs. The broader neuroscience community including clinicians and patients should convene to develop and advocate for such policy changes. © 2014 Elsevier Inc.
News Article | November 29, 2016
NEW YORK and SAN FRANCISCO, Nov. 29, 2016 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) announces Duygu Tosun-Turgut, PhD, assistant professor of radiology and biomedical imaging at UC San Francisco and co-director of the Center for Imaging of...
Sherer T.B.,The Michael J Fox Foundation For Parkinsons Research |
Chowdhury S.,The Michael J Fox Foundation For Parkinsons Research |
Peabody K.,The Michael J Fox Foundation For Parkinsons Research |
Brooks D.W.,The Michael J Fox Foundation For Parkinsons Research
Movement Disorders | Year: 2012
Improved symptomatic and disease-modifying treatments are needed for Parkinson's disease (PD). Although significant advances have been made in the understanding of PD etiology, the translation of these discoveries into novel transformative therapies has been limited as a result of systemic challenges in PD drug development. Preclinical testing lacks clear standards and prioritization criteria for advancing therapies to the clinic. Clinical testing is marked by expensive, long, and uninformative studies. In parallel to these scientific challenges, funding of late-stage drug development has become increasingly scarce and risk averse. In this context, novel models of collaboration and funding are opening up new avenues for pursuing treatments. This review will discuss the most critical challenges in PD drug development and the innovative approaches being developed to overcome these hurdles. © 2012 Movement Disorder Society.
Ko W.K.D.,Motac Neuroscience Ltd |
Ko W.K.D.,Institut Universitaire de France |
Ko W.K.D.,French National Center for Scientific Research |
Pioli E.,Motac Neuroscience Ltd |
And 8 more authors.
Movement Disorders | Year: 2014
Amantadine, an N-methyl-D-aspartate glutamate receptor antagonist, is currently the only pharmacological treatment for levodopa-induced dyskinesia (LID) in Parkinson's disease (PD), but causes adverse effects on the central nervous system at therapeutic doses. Fenobam, a negative modulator of metabotropic glutamate receptor subtype 5, has recently been reported to attenuate LID in MPTP-treated macaques. The aim of the current study was to investigate the treatment interactions of fenobam and amantadine on LID in the MPTP-treated macaque model of PD. The antidyskinetic and -parkinsonian effects were measured after administration of fenobam (10-30 mg/kg) and amantadine (10-30 mg/kg) alone and in combination. Fenobam (30 mg/kg) and amantadine (30 mg/kg) alone reduced LID, whereas lower doses of either drug did not cause any significant effects. A combined treatment of fenobam and amantadine at subthreshold doses (10 and 20 mg/kg) significantly reduced LID without worsening PD disability. These data suggest that a low-dose combination of fenobam and amantadine can be used for alleviating dyskinesia without causing adverse motor effects. Such combined therapies may offer a new therapeutic strategy for treatment of LID in PD patients. © 2014 International Parkinson and Movement Disorder Society.
News Article | November 28, 2016
JERUSALEM, November 28, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces it has entered into an agreement with the Michael J. Fox...
News Article | November 15, 2016
NEW YORK, Nov. 15, 2016 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) announces that Susan Bressman, MD, chair of the Department of Neurology at Mount Sinai Beth Israel, and Laurie Ozelius, PhD, associate neuroscientist and associate professor of...
News Article | November 15, 2016
NEW YORK, Nov. 15, 2016 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has conferred the 2016 Robert A. Pritzker Prize for Leadership in Parkinson's Research to Ira Shoulson, MD, professor of neurology, pharmacology and human science and director...
News Article | February 28, 2017
WASHINGTON, Feb. 28, 2017 /PRNewswire-USNewswire/ -- As part of The Michael J. Fox Foundation for Parkinson's Research (MJFF) 2017 Parkinson's Policy Forum, Michael J. Fox met with bipartisan members of the House of Representatives today to urge lawmakers to support policies that...